Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
David Strayer
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
[[File:David Strayer.png|200px|thumb|right|Source:GlobeNewswire]] '''David R. Strayer,''' M.D. is the Chief Scientific & Medical Officer of [[Hemispherx Biopharma]], the makers of [[Ampligen]]. Formerly a Professor of Medicine at the Medical College of Pennsylvania and Hahnemann University from 1987 to 1998. Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. Principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health.<ref name="Hem, Management"/> ==Notable studies== *1994, [[Ampligen]] inhibits human [[Human herpesvirus 6|herpesvirus-6]] in vitro<ref name="Ablashi, 1994"/> [https://www.ncbi.nlm.nih.gov/pubmed/7893986 (Abstract)] *1994, A controlled clinical trial with a specifically configured RNA drug, [[Ampligen|poly(I).poly(C12U)]], in [[chronic fatigue syndrome]]<ref name="Strayer,1994"/> [http://www.ncbi.nlm.nih.gov/pubmed/8148460 (Abstract)] *1995, Long Term Improvements in Patients with [[Chronic Fatigue Syndrome]] Treated with [[Ampligen]]<ref name="Strayer,1995"/> [https://scholars.opb.msu.edu/en/publications/long-term-improvements-in-patients-with-chronic-fatigue-syndrome- (Abstract)] *2001, Assessment of Functional Impairment by [[Two-day cardiopulmonary exercise test|Cardiopulmonary Exercise Testing]] in Patients with [[Chronic Fatigue Syndrome]]<ref name="VanNess, 2001"/> [http://www.tandfonline.com/doi/abs/10.1300/J092v08n03_09 (Abstract)] *2005, [[Exercise]] capacity and immune function in male and female patients with [[Chronic Fatigue Syndrome]]<ref name="Snell, 2005"/> [[http://iv.iiarjournals.org/content/19/2/387.full.pdf (Full Text)] *2007, Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine<ref> Takeshi Ichinohe, Shin-ichi Tamura, Akira Kawaguchi, Ai Ninomiya, Masaki Imai, Shigeyuki Itamura, Takato Odagiri, Masato Tashiro, Hidehiro Takahashi, Hirofumi Sawa, William M. Mitchell, David R. Strayer, William A. Carter, Joe Chiba, Takeshi Kurata, Tetsutaro Sata and Hideki Hasegawa. The Journal of Infectious Diseases, Vol. 196, No. 9 (Nov. 1, 2007), pp. 1313-1320. Url: http://www.jstor.org/stable/30086851</ref> [http://www.jstor.org/stable/30086851?seq=1#page_scan_tab_contents (Abstract)] *2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist [[rintatolimod]] in severe cases of [[chronic fatigue syndrome]]<ref name="Strayer, 2012"/> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031334 (Full Text)] *2015, Low [[Natural killer cell|NK Cell]] Activity in [[Chronic Fatigue Syndrome]] (CFS) and Relationship to Symptom Severity<ref name="strayer2015"/> [https://www.omicsonline.org/open-access/low-nk-cell-activity-in-chronic-fatigue-syndrome-cfs-and-relationship-to-symptom-severity-2155-9899-1000348.pdf (Full Text)] *2015, [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)]]: Characteristics of Responders to [[Rintatolimod]]<ref name="Strayer, 8Aug2015"/> [https://sciforschenonline.org/journals/drug/article-data/JDRD-1-103/JDRD-1-103.pdf (Full Text)] ==References== <references> <ref name="Ablashi, 1994"> {{Citation | last1 = Ablashi | first1 = DV | author-link1 = Dharam Ablashi | last2 =Berneman | first2 = ZN | authorlink2 = | last3 = Williams | first3 = M | author-link3 = | last4 = Strayer | first4 = D | author-link4 = David Strayer | last5 = Kramarsky | first5 = B | author-link5 = | last6 = Suhadolnik | first6 = RJ | author-link6 = | last7 =Reichenbach | first7 = N | author-link7 = | last8 =Hiltzges | first8 = P | author-link8 = | last9 = Komaroff | first9 = AL | author-link9 = Anthony Komaroff | title = Ampligen inhibits human herpesvirus-6 in vitro | journal = In Vivo | volume = 8 | issue = 4 | page = 587-91 | date = 1994 | pmid = 7893986 | doi = }}</ref> <ref name="Hem, Management"> {{Citation | title = Hemispherx Biopharma Management | url = http://www.hemispherx.net/management.php }}</ref> <ref name="Snell, 2005">{{citation | last1 = Snell | first1 = Christopher R | author-link1 = Christopher Snell | last2 =Van Ness | first2 = J Mark | author-link2 = Mark VanNess | last3 = Strayer | first3 = David R | author-link3 = David Strayer | last4 = Stevens | first4 = Staci R | author-link4 = Staci Stevens | title = Exercise capacity and immune function in male and female patients with Chronic Fatigue Syndrome (CFS) | journal = In Vivo | volume = 19 | page = 387-390 | date = 2005 | pmid = 15796202 | url = http://iv.iiarjournals.org/content/19/2/387.full.pdf }}</ref> <ref name="Strayer, 8Aug2015"> {{Citation | last1 = Strayer | first1 = David R | author-link1 = David Strayer | last2 =Stouch | first2 = Bruce C | authorlink2 = | last3 = Stevens | first3 = Staci R. | author-link3 = Staci Stevens | last4 = Bateman | first4 = Lucinda | author-link4 = Lucinda Bateman | last5 =Lapp | first5 = Charles W | author-link5 = Charles Lapp | last6 = Peterson | first6 = Daniel L | author-link6 = Daniel Peterson | last7 = Carter | first7 = William A | author-link8 = William Carter | last8 =Mitchell | first8 = William M | author-link8 = William Mitchell | title = Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod | journal = Journal of Drug Research and Development | volume = 1 | issue = 1 | date = 8 August 2015 | doi = 10.16966/2470-1009.103 | url = https://sciforschenonline.org/journals/drug/article-data/JDRD-1-103/JDRD-1-103.pdf }}</ref> <ref name="Strayer,1994"> {{Citation | last1 = Strayer | first1 = DR | author-link1 = David Strayer | last2 =Carter | first2 = WA | authorlink2 = William Carter | last3 = Brodsky | first3 = I | author-link3 = | last4 = Cheney | first4 = P | author-link4 = Paul Cheney | last5 = Peterson | first5 = D | author-link5 = Daniel Peterson | last6 = Salvato | first6 = P | author-link6 = | last7 =Thompson | first7 = C | author-link7 = | last8 =Loveless | first8 = M | author-link8 = | last9 = Shapiro | first9 = DE | author-link9 = | last10 = Elsasser | first10 = W | author-link10 = | title = A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome | journal = Clinical Infectious Diseases | volume = 18 | issue = Suppl 1 | page = S88-95 | date = 1994 | pmid = 8148460 | url = http://www.ncbi.nlm.nih.gov/pubmed/8148460 }}</ref> <ref name="Strayer,1995"> {{Citation | last1 = Strayer | first1 = DR | author-link1 = David Strayer | last2 =Carter | first2 = W | authorlink2 = William Carter | last3 = Strauss | first3 = KI | author-link3 = Kenneth Strauss | last4 = Brodsky | first4 = I | author-link4 = | last5 =Suhadolnik | first5 = R | author-link5 = | last6 = Ablashi | first6 = D | author-link6 = Dharam Ablashi | last7 =Henry | first7 = B | author-link7 = | last8 =Mitchell | first8 = WM | author-link8 = William Mitchell | last9 = Bastien | first9 = S | author-link9 = | last10 = Peterson | first10 = D | author-link10 = Daniel Peterson | title = Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen | journal = Journal of Chronic Fatigue Syndrome | volume = 1 | issue = 1 | page = 35-53 | date = 1995 | doi = 10.1300/J092v01n01_04 }}</ref> <ref name="Strayer, 2012"> {{Citation | last1 = Strayer | first1 = DR | author-link1 = David Strayer | last2 =Carter | first2 = WA | authorlink2 = William Carter | last3 = Stouch | first3 = BC | author-link3 = | last4 = Stevens | first4 = SR | author-link4 = Staci Stevens | last5 =Bateman | first5 = L | author-link5 = Lucinda Bateman | last6 = Cimoch | first6 = PJ | author-link6 = | last7 =Lapp | first7 = CW | author-link8 = Charles Lapp | last8 =Peterson | first8 = DL | author-link8 = Daniel Peterson | last9 = Chronic Fatigue Syndrome AMP-516 Study Group | author-link9 = | last10 = Mitchell | first10 = WM | author-link10 = William Mitchell | title = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. | journal = PLoS One | volume = 7 | issue = 3 | page = e31334 | date = 2012 | pmid = 22431963 | doi = 10.1371/journal.pone.0031334 }}</ref> <ref name="strayer2015">{{Citation| doi = 10.4172/2155-9899.1000348| issn = 2155-9899| pages = 1β9| last1 = Strayer | first1 = David | last2 = Scott | first2 = Victoria | last3 = Carter | first3 = William| title = Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Symptom Severity| journal = Journal of Clinical & Cellular Immunology | date = 2015-07-29| url = http://www.omicsonline.org/open-access/low-nk-cell-activity-in-chronic-fatigue-syndrome-cfs-and-relationship-to-symptom-severity-2155-9899-1000348.php?aid=59415}}</ref> <ref name="VanNess, 2001"> {{Citation | last1 = VanNess | first1 = J Mark| author-link1 = Mark VanNess | last2 =Snell | first2 = Christopher R | authorlink2 = Christopher Snell | last3 = Fredrickson | first3 = Dean M. | author-link3 = | last4 = Strayer | first4 = David R. | author-link4 = David Strayer | last5 =Stevens | first5 = Staci R | author-link5 = Staci Stevens | title = Assessment of Functional Impairment by Cardiopulmonary Exercise Testing in Patients with Chronic Fatigue Syndrome | journal = Journal of Chronic Fatigue Syndrome | volume = 8 | issue = 3-4 | page = 103-109 | date = 2001 | pmid = | doi = 10.1300/J092v08n03_09 }}</ref> </references> [[Category:Researchers]] [[Category:US researchers]]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Templates used on this page:
Template:Citation
(
edit
)
Module:Citation/CS1
(
edit
)
Module:Citation/CS1/COinS
(
edit
)
Module:Citation/CS1/Configuration
(
edit
)
Module:Citation/CS1/Date validation
(
edit
)
Module:Citation/CS1/Identifiers
(
edit
)
Module:Citation/CS1/Utilities
(
edit
)
Module:Citation/CS1/Whitelist
(
edit
)
Module:No globals
(
edit
)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs